These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21517709)

  • 1. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions.
    Katz N; Dart RC; Bailey E; Trudeau J; Osgood E; Paillard F
    Am J Drug Alcohol Abuse; 2011 Jul; 37(4):205-17. PubMed ID: 21517709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.
    Stanos SP; Bruckenthal P; Barkin RL
    Mayo Clin Proc; 2012 Jul; 87(7):683-94. PubMed ID: 22766088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet.
    Cone EJ
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S31-9. PubMed ID: 16458455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription opioid abuse among enrollees into methadone maintenance treatment.
    Rosenblum A; Parrino M; Schnoll SH; Fong C; Maxwell C; Cleland CM; Magura S; Haddox JD
    Drug Alcohol Depend; 2007 Sep; 90(1):64-71. PubMed ID: 17386981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
    Gasior M; Bond M; Malamut R
    Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harms of prescription opioid use in the United States.
    Imtiaz S; Shield KD; Fischer B; Rehm J
    Subst Abuse Treat Prev Policy; 2014 Oct; 9():43. PubMed ID: 25352167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abuse-deterrent formulations: part 1 - development of a formulation-based classification system.
    Mastropietro DJ; Omidian H
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):193-204. PubMed ID: 25374404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abuse of prescription drugs and the risk of addiction.
    Compton WM; Volkow ND
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S4-7. PubMed ID: 16563663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers?
    Edlund MJ; Sullivan M; Steffick D; Harris KM; Wells KB
    Pain Med; 2007; 8(8):647-56. PubMed ID: 18028043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A brief survey to characterize oxycodone abuse patterns in adolescents enrolled in two substance abuse recovery high schools.
    Osgood ED; Eaton TA; Trudeau JJ; Katz NP
    Am J Drug Alcohol Abuse; 2012 Mar; 38(2):166-70. PubMed ID: 22220502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.
    Butler SF; Cassidy TA; Chilcoat H; Black RA; Landau C; Budman SH; Coplan PM
    J Pain; 2013 Apr; 14(4):351-8. PubMed ID: 23127293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction of low dose transdermal buprenorphine -- did it influence use of potentially addictive drugs in chronic non-malignant pain patients?
    Skurtveit S; Furu K; Kaasa S; Borchgrevink PC
    Eur J Pain; 2009 Oct; 13(9):949-53. PubMed ID: 19095476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.
    Butler SF; Black R; Grimes Serrano JM; Folensbee L; Chang A; Katz N
    Pain Med; 2010 Jan; 11(1):81-91. PubMed ID: 20002324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription opioid abuse and tampering in the United States: results of a self-report survey.
    Vietri J; Joshi AV; Barsdorf AI; Mardekian J
    Pain Med; 2014 Dec; 15(12):2064-74. PubMed ID: 24931057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and evaluation of a tampering resistant transdermal fentanyl patch.
    Cai B; Engqvist H; Bredenberg S
    Int J Pharm; 2015 Jul; 488(1-2):102-7. PubMed ID: 25913120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden of the nonmedical use of prescription opioid analgesics.
    Gilson AM; Kreis PG
    Pain Med; 2009 Jul; 10 Suppl 2():S89-100. PubMed ID: 19691688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation.
    Peacock A; Degenhardt L; Hordern A; Larance B; Cama E; White N; Kihas I; Bruno R
    Int J Drug Policy; 2015 Dec; 26(12):1265-72. PubMed ID: 26123898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
    Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volume of prescription opioids used nonmedically in the United States.
    Katz NP; Birnbaum HG; Castor A
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):141-4. PubMed ID: 20504136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.